Woolsey Pharmaceuticals Completes Patient Recruitment for High-Dose Cohort of ALS Study
NEW YORK, Nov. 12, 2024 /PRNewswire/ -- Woolsey Pharmaceuticals today announced the successful completion of patient recruitment (n=31) in the high-dose (300 mg/day) cohort of the REAL study, which is


